THE JOURNAL OF
`Allergym Clinical
`Immunology
`VOLUME 127 0 NUMBER 2
`
`1%,]:
`
`ASTHMA & Ix-1x1um,».my
`
`AMERICAN ACADEMY OF ALLERGY,
`ASTHMA & IMMUNOLOGY
`
`201 'I AAAAI Annual Meeting
`
`San Francisco, CA
`
`March 'I8-March 22, 201 'I
`
`Program and abstracts of papers to be presented
`
`during scientific sessions
`
`Abstrad sessions programmed by the AAAAI
`
`J ALLERGY CUN IMMUNOL
`
`February 201 1
`
`1A
`
`Page 1 of 3
`
`CSL EXHIBIT 1047
`
`Page 1 of 3
`
`CSL EXHIBIT 1047
`
`

`

`
`
`THE JOURNAL OF
`Allergy“) Clinical
`
`VOLUME 127 o NUMBER 2
`
`
`M5]:
`AMERICAN ACADEMY or ALLERGY_AsTHMA s IMMUNomm
`
`Omcuu. Joumm. or 1H! AMERICAN ACADEMY or Aumcv, AerMA & IMMUNOLOGY
`
`Meeting Information
`
`Abstracts
`
`Late-Breaking Abstracts
`
`Saturday, March 19
`
`Sunday, March 20
`
`Monday, March 21
`
`Tuesday, March 22
`
`Scientific Program
`
`Alphabetic Index by Abstract Authors
`
`Keyword Index
`
`Author Disclosures
`
`Author Disclosures for Late-Breaking Abstracts
`
`3A
`
`A31
`
`A34
`
`A378
`
`A3153
`
`A8221
`
`A3271
`
`A3328
`
`A3352
`
`A3357
`
`A3410
`
`© 2011 American Academy of Allergy, Asthma & Immunology
`
`Statements and opinions expressed in the articles and communications herein are those of the authorts) and not necessarily those of the Editofls), the pub
`lisher, or the AAAAI. The Editor(s) and publisher disclaim any responsibility or liability for such material and do not guarMee, ml, or endorse any
`product or service advertised in this publication, nor do they guarantee any claim made by the manufacturer of such product or service.
`
`2A February 2011
`
`Page 2 0f 3
`
`J ALLERGY CLIN IMMUNOL
`
`Page 2 of 3
`
`

`

`J ALLERGY CLIN IMMUNOL
`FEBRUARY 2011
`
`391 Withdrawn
`
`392 Effect of Psychological Stress Intervention for Patients with
`
`Chronic Urticaria (CU)
`J. W. Tole, K. L. Gratz, N. D. Dave, S. K. Smith, G. D. Marshall; Univer
`sity of Mississippi Medical Center, Jackson, MS.
`RATIONALE: Many patients with CU report heightened levels of
`psychological stress before and/or after the onset of urticaria, thus we ob
`served the effect of psychological stress intervention on CU symptoms.
`METHODS: Participants met individually with a psychiatry resident once
`a week for a 6 week acceptance based behavioral stress intervention. Each
`participant completed a packet of psychological and dermatological symp
`tom questionnaires prior to the first session and after the final session. The
`urticaria activity score (UAS) was recorded daily to observe symptom
`trends. Medicines that would affect urticaria symptoms were recorded
`daily and each was given an arbitrary score (MS), based upon anticipated
`clinical impact, that was averaged over the period between visits to observe
`differences in drug use trends with intervention.
`RESULTS: Four participants were enrolled. Participants 1 and 4
`completed the study (Participant 2 withdrew due to schedule conflicts
`and Participant 3 was
`removed after missing several
`sessions).
`Participant 1 exhibited little change in the UAS or MS after intervention.
`There was an increase in both parameters across the final two sessions,
`which corresponded to an increase in major life stressors. There was an
`improvement in 2 of 3 stress questionnaire scores. Participant 4 exhibited
`an improvement in UAS and MS trends until the final session when a sig
`nificant life stressor was reported. There was improvement in 2 of 3 stress
`questionnaire scores.
`CONCLUSIONS: Psychological stress intervention may have treatment
`benefit for patients with CU and stress, but is likely limited by the time
`commitment required to learn the stress intervention techniques.
`
`AB104 Abstracts
`
`389 Pharmacokinetic Berinert P Study Of Subcutaneous Versus
`
`Intravenous Administration In Subjects With Moderate
`Hereditary Angioedema - The Passion Study
`I. Martinez-Saguer1, M. Cicardi2, E. Aygoren Pursun1, E. Rusicke1, T.
`Klingebiel1, W. Kreuz1; 11J. W. Goethe University Hospital Frankfurt,
`Germany, Frankfurt, GERMANY, 2Universita degli Studi di Milano, Di
`partimento di Scienze Cliniche, Italy, ITALY.
`RATIONALE: Hereditary angioedema (HAE) results from a congenital
`deficiency in C1 esterase inhibitor (C1 INH) that is characterized by
`unpredictable subcutaneous edema and mucosal swelling of respiratory
`and gastrointestinal tracts. Clinical studies (IMPACT 1 and 2) suggested
`that intravenously administered (i.v.) human C1 INH concentrate is an
`effective and safe treatment for acute angioedema attacks in patients
`with HAE. However, in patients who need i.v. treatment frequently, venous
`access may become limited over time, and concomitant thrombosis may be
`an issue. The current study compares the subcutaneous (s.c.) to the i.v. ad
`ministration route for pasteurized human C1 INH concentrate.
`METHODS: Twenty four subjects suffering from moderate HAE were
`randomized in a cross over design to either i.v. or s.c. treatment with
`1.000 U of pasteurized human C1 INH concentrate. Primary study end
`points comprised pharmacokinetics of C1 INH, plasma levels of C4 com
`plement, and safety variables of s.c. versus i.v. administration.
`RESULTS: After both, i.v. and s.c. administration, C1 INH plasma activ
`ity returned to baseline values after 7 days. Mean Cmax of C1 INH plasma
`activity was reached 15 minutes after i.v., and 48 hours after s.c. applica
`tion. Compared to i.v., bioavailability of human C1 INH concentrate was
`<50% if administered s.c. C4 plasma levels were compared after both ad
`ministration routes. Intravenous and s.c. administration of human C1 INH
`concentrate were well tolerated and no serious adverse events were re
`ported over the study period.
`CONCLUSIONS: The results suggest that s.c. administration of C1 INH
`leads to potentially clinically relevant C1 INH plasma levels in patients
`with moderate HAE and warrant further studies.
`
`390 The Chronic Urticaria Index as a Predictor of Responsiveness
`
`to Therapy
`M. J. Biagtan1, R. K. Viswanathan1, S. K. Mathur1,2; 1University of
`Wisconsin Hospitals and Clinics, Madison, WI, 2William S. Middleton
`Veterans Administration Hospital, Madison, WI.
`RATIONALE: The Chronic Urticaria (CU) Index serum test has been
`available to help identify patients with autoimmune urticaria. We sought
`to determine the clinical utility of the CU Index level, specifically with re
`spect to disease severity and responsiveness to medications.
`METHODS: In an IRB approved retrospective study of patients seen at the
`University of Wisconsin Allergy/Immunology clinic over a period of two
`years, patients with a diagnosis of chronic urticaria with a CU Index mea
`surement were reviewed. The clinical history of these patients was exam
`ined, specifically capturing the value of their CU Index as well as the
`therapeutic management utilized and whether subjective symptom control
`was achieved.
`RESULTS: We examined 62 patients. 42 patients remained symptomatic
`despite the use of antihistamines with or without leukotriene inhibitors (re
`fractory patients), and 20 were responsive (controlled patients). The prev
`alence of a positive CU Index (defined as a CU Index greater than or equal
`to 10) in refractory patients was significantly greater than in controlled pa
`tients (52% vs. 15%, p 0.006). Furthermore, the median CU Index for re
`fractory patients was significantly greater than in controlled patients (10.8
`vs. 5.05, p 0.009).
`CONCLUSIONS: A positive or elevated Chronic Urticaria Index value
`suggests an increased severity of chronic urticaria requiring a more aggres
`sive level of medication use to achieve control.
`
`SUNDAY
`
`Page 3 of 3
`
`